ToxStrategies, a Texas-based, multidisciplinary scientific consulting company, announced on Tuesday that it has acquired Clintrex Research Corporation, a Florida-based company that provides scientific, clinical trial, operational and regulatory assistance to pharmaceutical and biotech companies engaged in the development of new therapies for central nervous system disorders.

The acquired company was founded by Dr C. Warren Olanow, Dr Karl Kieburtz, and Cornelia Kamp. Terms of the transaction were not disclosed.

ToxStrategies partnered with Renovus Capital Partners in November 2022, with the aim of expanding its present client base and developing new end markets. The acquisition of Clintrex by ToxStrategies brings together two best-in-class firms within the life sciences industry, with a unified focus on providing integrated teams to solve the multifaceted problems and challenges faced by our clients, particularly in the drug development space. Drs Olanow and Kieburtz will continue to lead Clintrex as a Division of ToxStrategies.

President of ToxStrategies, Dr Laurie Couture Haws, PhD, DABT, ATS, said: "We are proud to welcome Clintrex physicians, scientists and regulatory specialists to our growing team of toxicologists, epidemiologists, biostatisticians, engineers, and health economics and outcome research (HEOR) analysts working to develop and assist with FDA approval of life-changing therapies, as well as providing expertise in the optimisation of the biopharmaceutical cold chain for novel, fragile, and temperature controlled therapies."